Clinical Trial Opening

For Adult Patients with Aggressive B-Cell NHL

Northside Cancer Institute Immunotherapy Program is opening a Phase II study to determine the antitumor activity, PK and safety of JCAR017 in subjects who have relapsed from, or are refractory to, frontline chemotherapy/immunotherapy for aggressive B-cell NHL and are ineligible for transplant.

northside.com/immunotherapy  |  bmtga.com
**Primary Objective**

To assess the antitumor activity of JCAR017 in adult subjects with aggressive B-cell NHL who are ineligible for HSCT.

**Inclusion Criteria**

- Age ≥ 18, ECOG PS 0-2.
- Diagnosis:  
  - DLBCL NOS or transformed from follicular lymphoma.  
  - High grade B-Cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology (double/triple hit lymphoma [DHL/THL]).  
  - Follicular lymphoma Grade 3B.
- Previous treatment must include single line of chemotherapy/immunotherapy containing an anthracycline and a CD20 targeted agent.
- Subjects must be deemed ineligible for both high-dose chemotherapy and HSCT based on age, performance status and organ dysfunction while also having adequate organ function for CAR T-cell treatment.

**Select Exclusion Criteria**

- Subjects with central nervous system CNS-only involvement by malignancy (note: subjects with secondary CNS involvement are allowed on study).
- Previous CD-19 targeted therapy and or prior hematopoietic stem cell transplant.

*ClinicalTrials.gov Identifier: NCT03483103*